Now showing items 1-3 of 3

    • Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. 

      Rambau, PF; Vierkant, RA; Intermaggio, MP; Kelemen, LE; Goodman, MT; Herpel, E; Pharoah, PD; Kommoss, S; Jimenez-Linan, M; Karlan, BY; Gentry-Maharaj, A; Menon, U; Polo, SH; Candido Dos Reis, FJ; Doherty, JA; Gayther, SA; Sharma, R; Larson, MC; Harnett, PR; Hatfield, E; de Andrade, JM; Nelson, GS; Steed, H; Schildkraut, JM; Carney, ME; Høgdall, E; Whittemore, AS; Widschwendter, M; Kennedy, CJ; Wang, F; Wang, Q; Wang, C; Armasu, SM; Daley, F; Coulson, P; Jones, ME; Anglesio, MS; Chow, C; de Fazio, A; García-Closas, M; Brucker, SY; Cybulski, C; Harris, HR; Hartkopf, AD; Huzarski, T; Jensen, A; Lubiński, J; Oszurek, O; Benitez, J; Mina, F; Staebler, A; Taran, FA; Pasternak, J; Talhouk, A; Rossing, MA; Hendley, J; AOCS Group; Edwards, RP; Fereday, S; Modugno, F; Ness, RB; Sieh, W; El-Bahrawy, MA; Winham, SJ; Lester, J; Kjaer, SK; Gronwald, J; Sinn, P; Fasching, PA; Chang-Claude, J; Moysich, KB; Bowtell, DD; Hernandez, BY; Luk, H; Behrens, S; Shah, M; Jung, A; Ghatage, P; Alsop, J; Alsop, K; García-Donas, J; Thompson, PJ; Swerdlow, AJ; Karpinskyj, C; Cazorla-Jiménez, A; García, MJ; Deen, S; Wilkens, LR; Palacios, J; Berchuck, A; Koziak, JM; Brenton, JD; Cook, LS; Goode, EL; Huntsman, DG; Ramus, SJ; Köbel, M (2018-10)
      We aimed to validate the prognostic association of p16 expression in ovarian high-grade serous carcinomas (HGSC) and to explore it in other ovarian carcinoma histotypes. p16 protein expression was assessed by clinical-grade ...
    • Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium. 

      Wentzensen, N; Poole, EM; Trabert, B; White, E; Arslan, AA; Patel, AV; Setiawan, VW; Visvanathan, K; Weiderpass, E; Adami, H-O; Black, A; Bernstein, L; Brinton, LA; Buring, J; Butler, LM; Chamosa, S; Clendenen, TV; Dossus, L; Fortner, R; Gapstur, SM; Gaudet, MM; Gram, IT; Hartge, P; Hoffman-Bolton, J; Idahl, A; Jones, M; Kaaks, R; Kirsh, V; Koh, W-P; Lacey, JV; Lee, I-M; Lundin, E; Merritt, MA; Onland-Moret, NC; Peters, U; Poynter, JN; Rinaldi, S; Robien, K; Rohan, T; Sandler, DP; Schairer, C; Schouten, LJ; Sjöholm, LK; Sieri, S; Swerdlow, A; Tjonneland, A; Travis, R; Trichopoulou, A; van den Brandt, PA; Wilkens, L; Wolk, A; Yang, HP; Zeleniuch-Jacquotte, A; Tworoger, SS (2016-08)
      <h4>Purpose</h4>An understanding of the etiologic heterogeneity of ovarian cancer is important for improving prevention, early detection, and therapeutic approaches. We evaluated 14 hormonal, reproductive, and lifestyle ...
    • SF3B1 mutations constitute a novel therapeutic target in breast cancer. 

      Maguire, SL; Leonidou, A; Wai, P; Marchiò, C; Ng, CK; Sapino, A; Salomon, A-V; Reis-Filho, JS; Weigelt, B; Natrajan, RC (2015-03)
      Mutations in genes encoding proteins involved in RNA splicing have been found to occur at relatively high frequencies in several tumour types including myelodysplastic syndromes, chronic lymphocytic leukaemia, uveal melanoma, ...